Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Study calls for range of diagnostic spinal fluid tests to help clinicians differentiate concurrent neurodegenerative diseases

, 26 August 2020/in E-News /by 3wmedia

In a series of studies Penn researchers demonstrated that, while tests created for AD are effectively diagnosing the condition when it’s clear cut, additional tests are needed to address the many cases with mixed pathology.
‘With the emergence of disease-modifying treatments for AD and other neurodegenerative diseases, it will be of utmost importance to accurately identify the underlying neuropathology in patients,’ said senior author John Q. Trojanowski, MD, PhD, professor of Pathology and Laboratory Medicine and co-director of the Center for Neurodegenerative Disease Research at Penn.
In one study, the Penn team compared results of a test looking at levels of tau and amyloid beta (Aß) in the spinal fluid, using two different types of analytical platforms. They determined that values from the two platforms could effectively be transformed into equivalent units, and these values accurately distinguished AD from FTLD. A cutoff of 0.34 for the t-tau:Aß1-42 ratio had 90 – 100 percent sensitivity and 91-96.7 percent specificity to differentiate FTLD cases, respectively.
In another study, the team looked at patient cases with more than one underlying neurodegenerative disease and compared the accuracy of the biomarkers using clinical and neuropathological diagnosis. They determined that cerebral spinal fluid (CSF) Aß and tau assays provided a valid diagnosis of AD but, in mixed pathology cases where Alzheimer’s was present along with other diseases (confirmed by autopsy), the testing strategies classified the diagnosis as AD alone.
‘We need to develop better CSF diagnostic panels for the early diagnosis of neurodegenerative dementias, including those due to mixed neurodegenerative disease pathologies that commonly co-occur with Alzheimer’s,’ said senior author Murray Grossman, MD, professor of Neurology and director of the Penn FTLD Center. Perelman School of Medicine

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:13:59Study calls for range of diagnostic spinal fluid tests to help clinicians differentiate concurrent neurodegenerative diseases

Genetic basis of drug resistance in sleeping sickness found

, 26 August 2020/in E-News /by 3wmedia

A scientist from the University of Glasgow, in partnership with others from the London School of Tropical Medicine, has uncovered the genetic basis for drug resistance in sleeping sickness.
Dr Harry De Koning, Reader of Biochemical Parasitology at the Institute of Infection, Immunity and Inflammation at the University of Glasgow, together with Dr David Horn and his colleagues at the London School of Hygiene and Tropical Medicine (LSHTM), have identified a genetic marker which will show whether a patient is resistant to drug treatment for African sleeping sickness.
African sleeping sickness, caused by infection with unicellular parasite Trypanosoma brucei, is endemic in many Sub-Saharan countries and almost invariably fatal.
Disease control relies almost entirely on chemotherapy as control of the tsetse fly vector is impracticable in the vast areas affected, and there is no vaccine.
Unfortunately, there are only a few, highly unsatisfactory drugs available to treat this infection. If the disease is diagnosed early, with the parasite proliferating in the peripheral bloodstream, the disease can usually be treated with injections of pentamidine but at the later stage, when the parasites have also penetrated the central nervous system, the routine treatment is with the arsenic-based drug melarsoprol, which is dangerously toxic and causes the death of an estimated 5% of the patients treated with it. Both drugs were introduced in the 1930s and their prolonged use has led to resistance in the parasites.
It has been known for decades that resistance to one of these drugs is usually associated with resistance to the other one as well, known as melarsoprol-pentamidine cross-resistance (MPXR), but for a long time the reason for this remained unknown.
Dr Harry de Koning discovered a few years ago that certain transport proteins on the surface of the trypanosome were involved in allowing both drugs entry into the parasite cell; loss of these transporters caused the MPXR phenotype. This discovery led to an effort to identify the genes controlling these transporters, funded by the Medical Research Council.
In a separate research programme, Dr David Horn and colleagues at LSHTM recently identified a cluster of channels for water and small metabolites (Aquaglyceroporins) in the Trypanosoma genome as a genetic determinant for MPXR. This resulted in a highly productive collaboration between the LSHTM and Glasgow teams. The findings revealed that one of the water/metabolite channels, Trypanosoma brucei Aquaglyceroporin 2, is indeed the genetic determinant of MPXR as deletion of this one gene (but not of other channels) caused significant resistance to both drugs. In addition, the gene was found to be disrupted in multi-drug resistant trypanosomes.
Identification of a genetic marker for multi-drug resistance will finally enable investigations into the scale of the MPXR problem in endemic countries and will hopefully prove to be sufficiently robust to underpin treatment decisions for individual patients who will then be spared dangerous treatment that would not cure them. University of Glasgow

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:13:47Genetic basis of drug resistance in sleeping sickness found

Molecular subtypes and genetic alterations may determine response to lung cancer therapy

, 26 August 2020/in E-News /by 3wmedia

Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient’s individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient’s response to therapy.
A UNC-led team of scientists has shown for the first time that lung cancer molecular subtypes correlate with distinct genetic alterations and with patient response to therapy. These findings in pre-clinical models and patient tumour samples build on their previous report of three molecular subtypes of non-small cell lung cancer and refines their molecular analysis of tumours.
Study senior author, Neil Hayes, MD, MPH, associate professor of medicine, says, ‘It has been known for about a decade of using gene expression arrays that ‘molecular subtypes’ exist. These subtypes have molecular ‘fingerprints’ and frequently have different clinical outcomes. However, the underlying etiologies of the subtypes have not been recognised. Why do tumours form subtypes?
‘Our study shows that tumour subtypes have different underlying alterations of DNA as part of the difference. These differences are further evidence of the importance of subtypes and the way we will use them. For example, the mutations are different which may imply much more ability to target than previously recognised. Also, we are starting to get a suggestion that these subtypes may reflect different cells of origin that rely on different cancer pathways. This is further unlocking the diversity of this complex disease.’ Hayes is a member of UNC Lineberger Comprehensive Cancer Center.
The team first defined and reported in 2006 on three lung cancer molecular subtypes, named according to their genetic pattern – bronchoid, squamoid and magnoid.
In this paper they sought to determine if distinct genetic mutations co-occur with each specific molecular subtypes. They found that specific genetic mutations were associated with each subtype and that these mutations may have independent predictive value for therapeutic response. Lineberger Clinical/Translational Developmental Research Award.

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:13:55Molecular subtypes and genetic alterations may determine response to lung cancer therapy

Scientists find unexpected new autism gene

, 26 August 2020/in E-News /by 3wmedia

Scientists from the Keck School of Medicine of USC have discovered the first gene associated with autism that has genome-wide significance. The discovery may allow researchers to more effectively study the causes of autism and develop new treatments for the disorder.
‘Our study shows that a highly significant genetic signal for autism pointed to a new gene, MSNP1AS,’ said Daniel B. Campbell, the study’s senior author and assistant professor of psychiatry and the behavioural sciences at the Keck School.
‘MSNP1AS is a non-coding RNA, which means it does not code for a protein. More than half of the RNAs made in the human brain are non-coding, but their functions are often unknown,’ he explained. ‘We found that expression of MSNP1AS is increased 12-fold in the brains of people with autism and discovered that it controls expression of a protein called moesin, which influences brain development and immune response. The discovery of a functional non-coding RNA opens new avenues of investigation for autism.’
Autism spectrum disorder (ASD) is a lifelong neuro-developmental disability characterised by problems with social interaction, communication and repetitive behaviours. The Centers for Disease Control and Prevention estimates that one in 88 children in the United States have an ASD.
ASD is highly heritable, suggesting that genetics are an important contributing factor, but many questions about its causes remain. There currently is no cure for the disorder.
A 2009 study published in Nature by Kai Wang, now assistant professor of psychiatry and preventive medicine at the Keck School, found a significant association of genetic risk factors underlying ASD with genetic markers on chromosome 5. The nearest genes (CDH9 and CDH10), however, were more than 1 million base pairs from the marker – too far to explain the link to autism.
Campbell and his team at the Keck School’s Zilkha Neurogenetic Institute hypothesised that a previously undetected genetic component might lie closer to the markers. Using bioinformatics techniques, they discovered that a new gene, MSNP1AS, was located directly at the autism-associated genetic markers. They also found that expression levels of the gene were higher in brain samples from autism patients than in samples from healthy individuals. They also demonstrated that overexpression of MSNP1AS caused a decrease in moesin protein.
‘The autism genetic signal gave us a treasure map with a big X over the Mojave Desert,’ Campbell said. ‘Instead of searching in the bright lights of Las Vegas or Los Angeles, the nearest big cities, we decided to search right under the big X on the map. We discovered the treasure [MSNP1AS] in the desert, just where the map said it was. And, once we found the treasure, we realised that it was a key to a mansion in Paris – that MSNP1AS regulates expression of moesin, a protein that is generated by a gene on the X chromosome [a different continent] and is known to impact both brain development and immune response.’
Previous studies showed that moesin RNA was central to a network of genes with altered expression in postmortem brain samples from people with autism. Like the previous studies, Campbell and his colleagues found that moesin RNA levels were increased in those brain samples, while actual moesin protein levels were not.
‘This suggests that MSNP1AS RNA may play a role in suppressing moesin protein expression, which may increase the risk for autism,’ said Tara Kerin, the study’s lead author and a Ph.D. candidate in preventive medicine at the Keck School.
While their results hinted that both MSNP1AS and moesin potentially could be targets for therapy, there is simply too much information that remains a mystery.
‘This is just a first step,’ Kerin said. ‘It’s just another clue that may help unlock the puzzle that we have before us.’ Keck School of Medicine

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:14:02Scientists find unexpected new autism gene

Premature birth linked to increased risk of mental health problems

, 26 August 2020/in E-News /by 3wmedia

One of the largest studies to investigate birth complications and later mental health has found that premature birth constitutes a single, independent risk factor for a range of severe psychiatric disorders. Researchers at King’s College London in the UK and Karolinska Institutet suggest that neurodevelopmental differences in those born prematurely may be important in understanding the link.
Researchers identified all individuals registered in the Swedish birth register between 1973 and 1985 who were alive and living in Sweden at the age of 16, a total of nearly 1.5 million individuals. By analysing national hospital discharge registers, they identified all individuals admitted to hospital with their first episode of a psychiatric disorder.
The study found that individuals born extremely prematurely (less than 32 weeks gestation) were 2.5 times more likely to have psychosis as young adults, nearly 3 times more likely to have depression, and 7.4 times more likely to have bipolar disorder than those born at term (37-41 weeks gestation). The findings also revealed a smaller, yet still significant, increased risk of developing bipolar disorder, psychosis and depression for those born moderately prematurely (32-36 weeks).
The study also investigated the link between premature birth, eating disorders and alcohol and drug dependency, but association with these disorders was much weaker. Other adverse perinatal factors including newborn health, maternal socio-demographic characteristics and maternal psychiatric history were taken into account and were found to have no significant effect on the findings.
‘We believe that the increased risk of mental disorders in those born very prematurely can be explained by alterations of brain development’, says Professor Christina Hultman at Karolinska Institutet, who led the Swedish part of the study. ‘The immature nervous system in these children is particularly vulnerable to brain injury resulting from birth complications.’
Approximately 6 percent of babies in Sweden are born prematurely every year. Thanks to research and new technology, today many of prematurely born can be saved. Most of these babies go on to lead healthy lifestyles, although as a group they are more likely to require extra school support and be hospitalised with a variety of physical problems. Therefore the authors point to the importance of raising awareness of the increased risk of mental health disorders in people born prematurely, and suggest gestational age should be considered when investigating risk factors for psychiatric disorders in young adults. Karolinska Institute

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:13:50Premature birth linked to increased risk of mental health problems

World’s first bedside genetic test endorsed

, 26 August 2020/in E-News /by 3wmedia

Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world’s first bedside genetic test has received acknowledgment by The Lancet. The article entitled ‘Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial’ reports on the use of a simple cheek swab test, the Spartan RX CYP2C19, performed by nurses at the patient’s bedside. This revolutionary technology allows patients with the genetic variant CYP2C19*2 to be rapidly identified. Cardiac stent patients with this variant are at risk of reacting poorly to standard anti-platelet therapy with Plavix (clopidogrel).
The study demonstrated that tailored drug treatment therapy made possible by genetic testing successfully protected all of the patients with the at-risk genetic variant from subsequent adverse events, while 30 per cent of patients treated with standard therapy did not receive adequate protection. The test is a significant step towards the realisation of personalised medicine.

http://tinyurl.com/cu8ruhu
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:13:57World’s first bedside genetic test endorsed

Inflammatory biomarkers improve the clinical prediction of mortality in COPD

, 26 August 2020/in E-News /by 3wmedia

The addition of changes in inflammatory biomarkers to established clinical variables improves the prediction of mortality in patients with chronic obstructive pulmonary disease (COPD), according to a new study.
‘COPD is characterised by low-grade inflammation, so we hypothesised that the addition of inflammatory biomarkers to established predictive factors would improve the prediction of mortality,’ said lead author Bartolome Celli, lecturer in medicine at Harvard Medical School and member of the Pulmonary and Critical Care Division of Brigham and Women’s Hospital in Boston. ‘We found that the addition of a panel of selected biomarkers to clinical variables significantly improved the ability of clinical variables to predict mortality in these patients.’
The researchers analysed prospectively collected data on 1,843 COPD patients from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Of these 1,843 patients, 168 (9.1%) died during the three-year follow-up.
Clinical predictors of morality included age, BODE (Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity) index , and incidence of hospitalisations due to exacerbation’s of COPD in the year prior to the study. A predictive model for mortality using these clinical variables had a C-statistic (which measures the ability of how well a clinical prediction rule can correctly rank-order patients by risk) of 0.686. Adding interleukin-6 (IL-6) to the predictive model significantly improved the C-statistic to 0.708, and the addition of a panel of biomarkers including white blood cell counts, IL-6, C-reactive protein (CRP), interleukin-8 (IL-8), fibrinogen, chemokine (C-C-motif) ligand 18 (CCL-18), and surfactant protein D (SP-D) further improved the C-statistic to 0.726.
‘This panel of selected biomarkers was not only elevated in non-survivors in our cohort, but was associated with mortality over three years of follow-up after adjusting for clinical variables known to predict mortality in patients with COPD,’ said Dr. Celli. ‘Except for IL-6, these biomarkers improved the predictive value of our model only marginally when considered individually, but they improved the model significantly when analyzed as a group.’
The study had several limitations, including the lack of a study adjudication committee to specify causes of death, the exclusion of some biomarkers thought to be important in the pathobiology of COPD, and the lack of a validating cohort.
‘Adding white blood cell counts and measurement of changes in systemic levels of IL-6, CRP, IL-8, fibrinogen, CCL-18, and SP-D significantly improves the ability of clinical variables to predict mortality in patients with COPD,’ said Dr. Celli. ‘This is the first study to show that the addition of biomarker levels to clinical predictors in COPD patients adds relevant prognostic information.’ EurekAlert

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:14:07Inflammatory biomarkers improve the clinical prediction of mortality in COPD

Mutation in gene IDH a possible target for AML treatment

, 26 August 2020/in E-News /by 3wmedia

Many patients with acute myeloid leukemia (AML) share a mutation in a gene called IDH. A University of Colorado Cancer Center study shows that this IDH mutation may be the first domino in a chain that leads to a more aggressive form of the disease.
‘In fact, it’s not IDH itself that causes the problem,’ says Dan Pollyea, MD, MS, investigator at the CU Cancer Center and assistant professor of haematologic oncology at the University of Colorado School of Medicine. Rather, the mutation in IDH leads to exponentially higher blood levels of a protein called 2-hydroxyglutarate. This protein ‘mucks up,’ as Pollyea says, other genes that in turn promote cancer or fail to inhibit its growth.
The recent study shows that AML patients in remission who retain high levels of 2-hydroxyglutarate – due universally to IDH mutation – are much more likely to relapse than patients without similarly elevated levels.
The chain of causation includes another couple links.
‘2-hydroxyglutarate reduces genes’ ability to regulate themselves,’ says Pollyea. Over time genes accumulate gunk in the form of methylation – these methyl groups attach to silence parts of gene promoters, helping to decide which genes are and are not turned into proteins. Too much methylation is associated with many cancers, including AML. And 2-hydroxyglutarate turns off one of the body’s methylation-regulating genes.
So an IDH mutation leads to high 2-hydroxyglutarate, leads to bad gene regulation, leads to hypermethylation, leads to AML.
Pollyea hopes to stop the first domino from falling by targeting IDH mutations. ‘Imagine screening for patients prospectively and then if they have the mutation, we could use something like an IDH inhibitor,’ Pollyea says. Turn off this mutation and doctors may be able to turn of the disease, or at least its most aggressive characteristics.
But the genetic testing for IDH mutation is currently costly and time consuming. And so Pollyea hopes to identify patients with the IDH mutation by looking downstream – tests for blood-levels of 2-hydroxyglutarate being developed at the CU Cancer Center could determine the patients most likely to benefit from an IDH inhibitor.
Finally, Pollyea and colleagues including molecular biologist James DeGregori, PhD, are exploring novel ways to target the IDH mutation. ‘I think that even beyond the very real promise of IDH inhibitor drugs, this is a potential weak spot for AML that can be targeted in a number of ways,’ Pollyea says. University of Colorado Cancer Center

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:13:45Mutation in gene IDH a possible target for AML treatment

Tongue analysis software developed at MU uses ancient Chinese medicine to warn of disease

, 26 August 2020/in E-News /by 3wmedia

For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify the overall physical status of the body, or zheng. Now, University of Missouri researchers have developed computer software that combines the ancient practices and modern medicine by providing an automated system for analysing images of the tongue.
‘Knowing your zheng classification can serve as a pre-screening tool and help with preventive medicine,’ said Dong Xu, chair of MU’s computer science department in the College of Engineering and study co-author. ‘Our software helps bridge Eastern and Western medicine, since an imbalance in zheng could serve as a warning to go see a doctor. Within a year, our ultimate goal is to create an application for smartphones that will allow anyone to take a photo of their tongue and learn the status of their zheng.’
The software analyses images based on the tongue’s colour and coating to distinguish between tongues showing signs of ‘hot’ or ‘cold’ zheng. Shades of red and yellow are associated with hot zheng, whereas a white coating on the tongue is a sign of cold zheng.
‘Hot and cold zheng doesn’t refer directly to body temperature,’ said Xu, who is also on the faculty of the Bond Life Sciences Center. ‘Rather, it refers to a suite of symptoms associated with the state of the body as a whole.’
For example, a person with cold zheng may feel chills and coolness in the limbs and show a pale flushing of face. Their voice may have a high pitch. Other symptoms of cold sheng are clear urine and loose stool. They also may prefer hot foods and drinks and desire warm environments.
In Chinese traditional medicine both hot and cold zheng can be symptoms of gastritis, an inflammation of the stomach lining frequently caused by bacterial infection.
For the study, 263 gastritis patients and 48 healthy volunteers had their tongues analysed. The gastritis patients were classified by whether they showed infection by a certain bacteria, known as Helicobacter pylori, as well as the intensity of their gastritis symptoms. In addition, most of the gastritis patients had been previously classified with either hot or cold zheng. This allowed the researchers to verify the accuracy of the software’s analysis.
‘Our software was able to classify people based on their zheng status,’ said study co-author Ye Duan, associate professor of computer science at MU.
‘As we continue to work on the software we hope to improve its ability,’ Duan said. ‘Eventually everyone will be able to use this tool at home using webcams or smartphone applications. That will allow them to monitor their zheng and get an early warning about possible ailments.’ University of Missouri

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:13:52Tongue analysis software developed at MU uses ancient Chinese medicine to warn of disease

Fat outside of arteries may influence onset of coronary artery disease

, 26 August 2020/in E-News /by 3wmedia

Researchers at UC have confirmed that fat surrounding the outside of arteries in humans—particularly the left coronary artery—may influence the onset of coronary artery disease, or atherosclerosis, which is the leading cause of death in the U.S.
These findings may help in identifying the molecular culprit, with the goal of creating targeted therapies for atherosclerosis before the disease forms.
Coronary artery disease is a narrowing of the small blood vessels that supply blood and oxygen to the heart.
Tapan Chatterjee, PhD, and researchers in the division of cardiovascular diseases at UC found through global gene expression analysis (measurement of the activity of thousands of genes at once) that this outer fat tissue—known as perivascular fat tissue—is different from subcutaneous (beneath the skin) fat tissues in other parts of the body.
Research has previously shown that perivascular fat tissue in humans with coronary artery diseases is highly inflamed, leading to the belief that dysfunctional perivascular fat is the real culprit in the formation of coronary artery diseases.
Chatterjee’s team was able to replicate this inflammation in animal models.
‘The proximity of the perivascular fat to the artery easily influences the function of the coronary blood vessel wall,’ Chatterjee says. ‘The perivascular fat is very sensitive to high-fat diet induced inflammatory changes in mice. We found that by transplanting perivascular fat from high-fat diet fed obese mice to the carotid artery of lean mice, the tissue was detrimental to the blood vessel wall and promptly caused disease to form there.
‘Our next steps will be to identify various secreted factors, or signals, from perivascular fat tissue of obese mice that could negatively influence the functions of the blood vessel wall,’ he continues. ‘We believe this cross-talk between perivascular fat and the coronary artery is very important in triggering coronary artery diseases. We hope this knowledge helps in targeting the molecules before the onset of coronary artery diseases and treating patients before they ever experience the disease.’ University of Cincinnati Academic Health Center

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:242021-01-08 11:14:00Fat outside of arteries may influence onset of coronary artery disease
Page 88 of 227«‹8687888990›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription